Gyre Therapeutics (NASDAQ:GYRE) Releases Earnings Results, Misses Estimates By $0.03 EPS

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) issued its quarterly earnings results on Monday. The company reported $0.01 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.04 by ($0.03), Zacks reports. The firm had revenue of $27.87 million during the quarter, compared to analyst estimates of $23.50 million. Gyre Therapeutics had a negative return on equity of 118.43% and a negative net margin of 84.57%.

Gyre Therapeutics Stock Down 4.4 %

Shares of NASDAQ GYRE traded down $0.45 during midday trading on Friday, reaching $9.78. The stock had a trading volume of 87,455 shares, compared to its average volume of 80,302. Gyre Therapeutics has a twelve month low of $8.26 and a twelve month high of $19.00. The company's 50 day moving average price is $11.31 and its 200 day moving average price is $12.23.

Insider Transactions at Gyre Therapeutics

In other news, President Songjiang Ma sold 2,000 shares of the business's stock in a transaction that occurred on Thursday, December 26th. The shares were sold at an average price of $12.70, for a total value of $25,400.00. Following the transaction, the president now owns 2,928,467 shares in the company, valued at approximately $37,191,530.90. The trade was a 0.07 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last 90 days, insiders have sold 36,054 shares of company stock worth $411,597. Company insiders own 19.52% of the company's stock.

Remove Ads

Institutional Inflows and Outflows

An institutional investor recently raised its position in Gyre Therapeutics stock. Bank of America Corp DE lifted its stake in shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE - Free Report) by 40.4% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 6,937 shares of the company's stock after acquiring an additional 1,996 shares during the period. Bank of America Corp DE's holdings in Gyre Therapeutics were worth $84,000 at the end of the most recent reporting period. 23.99% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Noble Financial began coverage on shares of Gyre Therapeutics in a research report on Tuesday, March 11th. They issued an "outperform" rating on the stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.